# FDA Approves ANDA for Upsher Smith Labs Upsher Smith Laboratories received FDA approval for ANDA216772 on June 12, 2024, expanding its generic drug portfolio and strengthening its competitive position in the pharmaceutical market. The approval could help the company capture additional market share in the generic segment while potentially offering cost savings to consumers and healthcare systems.